Novel esterases and uses thereof

Abstract

To provide an esterase having improved thermostability, which is usable for degrading polyester at an industrial level and with high yield.SOLUTION: The present invention relates to novel esterases, more specifically, esterase variants having improved thermostability as compared with esterases having a specific amino acid sequence, and uses thereof for degrading polyester-containing material, such as plastic products. The inventive esterases are particularly suitable for degrading polyethylene terephthalate and materials containing polyethylene terephthalate.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to novel esterases, more particularly esterases with improved thermostability compared to the parent esterases, and their use for degrading polyester-containing materials, such as plastic products. The esterases of the present invention are particularly suitable for degrading polyethylene terephthalate and materials containing polyethylene terephthalate.

[0002] background Esterases can catalyze the hydrolysis of various polymers, including polyesters. In this context, esterases have shown promising effects in many industrial applications, such as, for example, as detergents for dishwashing and laundry applications, as degradative enzymes for processing biomass and food, as biocatalysts in the detoxification of environmental pollutants or for the treatment of polyester fabrics in the textile industry. Similarly, the use of esterases as degradative enzymes for the hydrolysis of polyethylene terephthalate (PET) is of particular interest. Indeed, PET is used in many technical fields, such as, for example, in the manufacture of clothes, carpets, or in the form of a thermosetting resin for packaging or the manufacture of automotive plastics or other parts, and the accumulation of PET in landfills is an increasing ecological problem.

[0003] Of particular interest among esterases are cutinases, also known as cutin hydrolases (EC 3.1.1.74). Cutinases have been identified from various fungi (PE Kolattukudy in "Lipases", Ed. B. Borg-stroem and HL Brockman, Elsevier 1984, 471-504), bacteria, and plant pollen. Recently, metagenomic approaches have led to the identification of additional esterases.

[0004] Enzymatic degradation is considered as an interesting solution to reduce the accumulation of such plastic waste. Indeed, enzymes can accelerate the hydrolysis of polyester-containing materials, and more particularly plastic products, even down to the monomer level. Moreover, the hydrolyzates (i.e., monomers and oligomers) can be recycled as raw materials for synthesizing new polymers.

[0005] In this context, several esterases have been identified as potential degradative enzymes, for example several mutants of the esterase (cutinase) from Fusarium solani pisi have been published (Appl. Environm. Microbiol. 64, 2794-2799, 1998; Proteins: Structure, Function and Genetics 26,442-458,1996).

[0006] However, most of these esterases are not effective at industrial levels because they have poor resistance to high temperatures. Therefore, there is still a need for esterases with improved thermostability that can be used to degrade polyesters at industrial levels and with high yields.

[0007] Summary of the Invention The present invention provides novel esterase variants that exhibit improved thermostability compared to parent or wild-type esterases. These esterases are particularly useful in processes for degrading plastic materials and products, such as plastic materials and products containing PET. More particularly, the present invention provides esterase variants having an amino acid sequence as shown in SEQ ID NO: 1, which corresponds to amino acids 36-293 of the amino acid sequence of cutinase derived from metagenomic analysis described in Sulaiman et al., Appl Environ Microbiol. 2012 Mar., or amino acids 36-293 of the amino acid sequence referenced in SwissProt G9BY57.

[0008] In this regard, it is an object of the present invention to provide an esterase that (i) has at least 75%, 80%, 85%, 90%, 95% or 99% identity to the full-length amino acid sequence shown in SEQ ID NO:1, (ii) contains at least one amino acid modification compared to SEQ ID NO:1, (iii) has polyesterolytic activity, and (iv) exhibits improved thermostability compared to the esterase of SEQ ID NO:1.

[0009] More particularly, the esterase of the present invention is selected from the group consisting of D203+S248, E173, L202, N204, F208, A172+A209, G39, A103, L82, G53, L104, L107, L119, A121, L124, I54, M56, L70, L74, A127, V150, L152, L168, V170, P196, V198, V200, V219, Y220, T221, S223, W224, M225, L239, T252, N253, H256, S1, Y4, Q5, R6, N9, S13, T16, S22, T25, Y26, S34, Y43, S48, and Q258, wherein the positions are numbered by reference to the amino acid sequence shown in SEQ ID NO:1.

[0010] In certain embodiments, the esterase variants of the invention comprise one or more amino acid sequence substitution(s) compared to SEQ ID NO: 1 at position(s) selected from D203+S248, E173, N204, L202, F208, and V170. Preferably, the esterase variants of the invention comprise at least amino acid substitution(s) compared to SEQ ID NO: 1 at position(s) selected from D203+S248 and F208.

[0011] In another particular embodiment, the esterase variants of the invention comprise one or more amino acid substitution(s) compared to SEQ ID NO:1 at a position selected from T61, Y92, and V177, where the positions are numbered by reference to the amino acid sequence set forth in SEQ ID NO:1, and where the substitutions are different from T61A / G, Y92A, and V177A. Preferably, the esterase variants of the invention comprise one or more amino acid substitution(s) compared to SEQ ID NO:1 selected from V177I, Y92G, Y92P, Y92P+F208W, and T61M.

[0012] In certain embodiments, the esterase variants of the invention have, compared to the esterase of SEQ ID NO:1: at least one additional disulfide bridge; and / or at least one additional salt bridge; and / or - at least one mutation of an amino acid residue located in a solvent-exclusion cavity of the esterase cavity; and / or - suppression of at least one N-terminal and / or C-terminal amino acid residue may include.

[0013] Another object of the invention is to provide a nucleic acid encoding an esterase of the invention. The invention also relates to an expression cassette or expression vector comprising said nucleic acid, and to a host cell comprising said nucleic acid, expression cassette or vector.

[0014] A further object of the present invention is to (a) culturing a host cell according to the invention under conditions suitable for expressing a nucleic acid encoding an esterase; and optionally (b) recovering the esterase from the cell culture. The present invention provides a method for producing an esterase, comprising:

[0015] The present invention also provides (a) degrading a plastic product by contacting the plastic product with an esterase or a host cell according to the invention; and optionally (b) recovering the monomers and / or oligomers. The present invention also relates to a method for degrading a plastic product containing at least one polyester, comprising:

[0016] Detailed Description of the Invention definition The present disclosure will be best understood with reference to the following definitions.

[0017] As used herein, the terms "peptide", "polypeptide", "protein" and "enzyme" refer to a chain of amino acids linked by peptide bonds, regardless of the number of amino acids forming the chain. Amino acids are designated herein by their one-letter or three-letter codes according to the following nomenclature: A: alanine (Ala); C: cysteine ​​(Cys); D: aspartic acid (Asp); E: glutamic acid (Glu); F: phenylalanine (Phe); G: glycine (Gly); H: histidine (His); I: isoleucine (Ile); K: lysine (Lys); L: leucine (Leu); M: methionine (Met); N: asparagine (Asn); P: proline (Pro); Q: glutamine (Gln); R: arginine (Arg); S: serine (Ser); T: threonine (Thr); V: valine (Val); W: tryptophan (Trp) and Y: tyrosine (Tyr).

[0018] The term "esterase" refers to an enzyme belonging to the class of hydrolases classified as EC 3.1.1 according to the enzyme nomenclature, which catalyzes the hydrolysis of esters to acids and alcohols. The term "cutinase" or "cutin hydrolase" refers to an esterase classified as EC 3.1.1.74 according to the enzyme nomenclature, which is capable of catalyzing the chemical reaction producing cutin monomers from cutin and water.

[0019] The terms "wild-type protein" or "parent protein" are used synonymously and refer to the unmutated form of the polypeptide as it occurs in nature. In the present case, parent esterase refers to the esterase having the amino acid sequence as shown in SEQ ID NO:1.

[0020] Thus, the terms "mutant" and "variant" may be used synonymously and refer to a polypeptide derived from SEQ ID NO: 1 and containing modifications or changes, i.e. substitutions, insertions, and / or deletions, at one or more (e.g. several) positions and having polyesterolytic activity. The mutants can be obtained by various techniques well known in the art. In particular, examples of techniques for altering a DNA sequence encoding a wild-type protein include, but are not limited to, site-directed mutagenesis, random mutagenesis, and synthetic oligonucleotide construction.

[0021] The term "modified" or "altered" as used herein with respect to a position or amino acid means that the amino acid at a particular position is altered compared to the amino acid in the wild-type protein.

[0022] "Substitution" means that an amino acid residue is replaced by another amino acid residue. Preferably, the term "substitution" refers to the replacement of an amino acid residue by another amino acid residue selected from the 20 standard naturally occurring amino acid residues, rare naturally occurring amino acid residues (e.g. hydroxyproline, hydroxylysine, allohydroxylysine, 6-N-methyllysine, N-ethylglycine, N-methylglycine, N-ethylasparagine, allo-isoleucine, N-methylisoleucine, N-methylvaline, pyroglutamine, aminobutyric acid, ornithine, norleucine, norvaline), and non-natural amino acid residues that are often synthetically produced (e.g. cyclohexyl-alanine). Preferably, the term "substitution" refers to the replacement of an amino acid residue by another amino acid residue selected from the 20 standard naturally occurring amino acid residues (G, P, A, V, L, I, M, C, F, Y, W, H, K, R, Q, N, E, D, S, and T). The "+" symbol indicates a combination of substitutions. In this document, the following terms are used to indicate substitutions: L82A indicates that the amino acid residue at position 82 of the parent sequence (leucine, L) is changed to alanine (A). A121V / I / M indicates that the amino acid residue at position 121 of the parent sequence (alanine, A) is replaced by one of the following amino acids: valine (V), isoleucine (I), or methionine (M). Substitutions may be conservative or non-conservative. Examples of conservative substitutions are within the groups of basic amino acids (arginine, lysine, and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine, asparagine, and threonine), hydrophobic amino acids (methionine, leucine, isoleucine, cysteine, and valine), aromatic amino acids (phenylalanine, tryptophan, and tyrosine), and small amino acids (glycine, alanine, and serine).

[0023] The term "deletion" when used in reference to an amino acid means that the amino acid is removed or absent.

[0024] The term "insertion" means the addition of one or more amino acids.

[0025] Unless otherwise specified, positions disclosed in this application are numbered by reference to the amino acid sequence shown in SEQ ID NO:1.

[0026] The term "sequence identity" or "identity" as used herein refers to the number (or percentage expressed as a percentage) of matches (identical amino acid residues) between two polypeptide sequences. Sequence identity is determined by comparing sequences aligned to maximize overlap and identity while minimizing sequence gaps. In particular, sequence identity can be determined using any of a number of mathematical global or local alignment algorithms, depending on the length of the two sequences. Sequences of similar length are preferably aligned using a global alignment algorithm (e.g., the Needleman and Wunsch algorithm; Needleman and Wunsch, 1970) that optimally aligns the full length and sequences, while sequences of significantly different lengths are preferably aligned using a local alignment algorithm (e.g., the Smith and Waterman algorithm (Smith and Waterman, 1981) or the Altschul algorithm (Altschul et al., 1997; Altschul et al., 2005)). Alignment for purposes of determining amino acid sequence identity can be accomplished in a variety of ways that are within the skill of the art, for example, using publicly available computer software available on internet websites such as http: / / blast.ncbi.nlm.nih.gov / or http: / / www.ebi.ac.uk / Tools / emboss / . Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.For purposes herein, numerical % amino acid sequence identity refers to the numerical value calculated using the pairwise sequence alignment program EMBOSS Needle, which uses the Needleman-Wunsch algorithm to create an optimal global alignment of two sequences, with all search parameters set to default values, i.e., scoring matrix=BLOSUM62, gap open=10, gap extend=0.5, end gap penalty=false, end gap open=10, and end gap extend=0.5.

[0027] The terms "disulfide bridge," "disulfide bond," and "SS bond" are used synonymously and refer to a covalent bond between the sulfur atoms of two cysteines.

[0028] The term "salt bridge" or "ion pair" refers to a non-covalent electrostatic interaction between two oppositely charged residues in a protein. A salt bridge is formed by the anion carboxylate (RCOO) of either aspartic acid or glutamic acid. - ) and the cationic ammonium moiety of lysine (RNH3 + ) or the guanidinium moiety of arginine (RNHC(NH2)2 + ). Other amino acid residues with ionizable side chains, such as histidine, tyrosine, serine, threonine, and cysteine, can also be part of a salt bridge.

[0029] The term "glycosylation" with respect to a polypeptide means that one or several glycans are attached to at least one amino acid residue of the polypeptide. In the context of the present invention, glycosylation includes N-linked glycans attached to the amide nitrogen of an asparagine residue, O-linked glycans attached to the hydroxyl oxygen of a serine or tyrosine residue, and C-linked glycans attached to the carbon of a tryptophan residue.

[0030] "Protein conformation" or "crystal structure" refers to the three-dimensional structure of a protein.

[0031] The term "recombinant" refers to a nucleic acid construct, vector, polypeptide, or cell that has been produced by genetic engineering.

[0032] As used herein, the term "expression" refers to any process involved in the production of a polypeptide, including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

[0033] The term "expression cassette" refers to a nucleic acid construct that includes a coding region (ie, a nucleic acid of the invention) and a regulatory region (ie, containing one or more control sequences that are operably linked).

[0034] As used herein, the term "expression vector" refers to a DNA or RNA molecule that contains an expression cassette of the present invention. Preferably, the expression vector is a linear or circular double-stranded DNA molecule.

[0035] "Polymer" refers to a compound or mixture of compounds whose structure is composed of multiple monomers (repeating units) linked by covalent chemical bonds. In the context of the present invention, the term polymer includes natural or synthetic polymers composed of one type of repeating unit (i.e., homopolymers) or a mixture of different repeating units (i.e., copolymers or heteropolymers). According to the present invention, "oligomer" refers to a molecule containing from 2 to about 20 monomers.

[0036] In the context of the present invention, "polyester-containing material" or "polyester-containing product" refers to a product, such as a plastic product, that contains at least one polyester in crystalline, semi-crystalline, or completely amorphous form. In a particular embodiment, polyester-containing material refers to any item made of at least one plastic material, such as plastic sheets, plastic tubes, plastic rods, plastic profiles, plastic shapes, plastic films, plastic chunks, etc., that contains at least one polyester and possibly other substances or additives, such as plasticizers, mineral, or organic fillers. In another particular embodiment, polyester-containing material refers to a plastic compound or plastic construction in a molten or solid state that is suitable for making a plastic product.

[0037] As used herein, "polyester" includes, but is not limited to, polyethylene terephthalate (PET), polytrimethylene terephthalate (PTT), polybutylene terephthalate (PBT), polyethylene isosorbide terephthalate (PEIT), polylactic acid (PLA), polyhydroxyalkanoic acid (PHA), polybutylene succinate (PBS), polybutylene succinate adipate (PBSA), polybutylene adipate terephthalate (PBAT), polyethylene furanoate (PEF), polycaprolactone (PCL), poly(ethylene adipate) (PEA), polyethylene naphthalate (PEN), and blends / mixtures of these polymers.

[0038] Novel esterases with improved thermostability The present invention provides novel esterases with improved thermostability. More specifically, the inventors have developed various methods to improve the stability of esterases at high temperatures, advantageously above 50° C., which allows the design of novel enzymes with superior properties for use in industrial processes.

[0039] With the aim of improving the stability and / or activity of esterases under conditions where industrial degradation of plastic products can be carried out, the present inventors have developed novel esterases that are highly resistant to temperature and are derived from the esterase of SEQ ID NO: 1. The esterases of the present invention are particularly suitable for degrading plastic products containing PET.

[0040] The present invention shows that by creating new disulfide bridge(s) and / or salt bridge(s) in the crystal structure of the protein; by reducing the mobility of the protein and / or the solvent excluded volume of the internal cavity; and / or by reducing the N- or C-terminal extremities, novel proteins are obtained that exhibit polyesterolytic activity with improved thermal stability.

[0041] It is therefore an object of the present invention to provide an esterase that (i) has at least 75%, 80%, 85%, 90%, 95% or 99% identity to the full-length amino acid sequence shown in SEQ ID NO:1, (ii) contains at least one amino acid modification compared to SEQ ID NO:1, (iii) has polyesterolytic activity, and (iv) exhibits improved thermostability compared to the esterase of SEQ ID NO:1.

[0042] In the context of the present invention, the term "improved thermostability" refers to an improved ability of the enzyme to withstand changes in its chemical and / or physical structure at elevated temperatures, more particularly at temperatures between 50°C and 90°C, compared to the esterase of SEQ ID NO:1. Such an improvement is typically about 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, or more. In particular, the esterase of the present invention may exhibit an increased melting temperature (Tm) compared to the esterase of SEQ ID NO:1. In the context of the present invention, the melting temperature refers to the temperature at which half of the population of the protein / enzyme under consideration is unfolded or misfolded. Typically, the esterase of the present invention exhibits an increased Tm of about 1°C, 2°C, 3°C, 4°C, 5°C, 10°C, or more, compared to the Tm of the esterase of SEQ ID NO:1.

[0043] In particular, the esterase of the present invention may have an extended half-life at temperatures between 50° C. and 90° C. compared to the esterase of SEQ ID NO: 1. Furthermore, at such temperatures, the esterase of the present invention may exhibit higher decomposition activity compared to the esterase of SEQ ID NO: 1.

[0044] The thermal stability of a protein can be evaluated by the skilled artisan according to methods known per se in the art. For example, the thermal stability can be evaluated by analysis of protein folding using circular dichroism. Alternatively or additionally, the thermal stability can be evaluated by measuring the residual esterase activity and / or the residual polyester depolymerization activity of the enzyme after incubation at various temperatures. The ability to perform multiple polyester depolymerization assays at various temperatures can also be evaluated. A rapid and valuable test can consist of evaluating the ability of the enzyme to degrade solid polyester compounds dispersed on an agar plate after incubation at various temperatures by measuring the diameter of the circular halo. Preferably, differential scanning fluorimetry (DSF) is performed to evaluate the thermal stability of the protein / enzyme. More particularly, DSF can be used to quantify the change in the thermal denaturation temperature of a protein and thus determine its melting point (Tm). In the context of the present invention, unless otherwise stated, Tm is measured using DSF as shown in the experimental part. In the context of the present invention, comparisons of Tm are made with Tm measured under the same conditions (eg, pH, nature and amount of polyester, etc.).

[0045] In certain embodiments, the variants of the invention have both improved thermostability and increased polyesterolytic activity compared to the esterase of SEQ ID NO:1.

[0046] In the context of the present invention, the term "increased activity" or "increased degradation activity" refers to an increased ability of an enzyme to degrade plastic products or materials, more particularly polyester-containing plastic products or materials, compared to the esterase of SEQ ID NO: 1. Such an increase is typically about 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, or more. In particular, the esterase variants have a polyester degradation activity that is at least 10% higher, preferably at least 20%, 50%, 100%, 200%, 300%, or more higher, compared to the polyester degradation activity of the esterase of SEQ ID NO: 1.

[0047] The activity of a protein can be evaluated by a person skilled in the art according to methods known per se in the art. For example, the activity can be evaluated by measuring the specific esterase activity, the specific polyester depolymerization activity, the rate of decomposing a solid polyester compound dispersed on an agar plate, or the specific polyester depolymerization activity in a reactor.

[0048] In the context of the present invention, the term "specific activity" or "degradation specific activity" refers to the initial rate of oligomers and / or monomers released when a polyester-containing plastic article is contacted with a degradative enzyme, such as an esterase as described in the present invention, under appropriate temperature, pH, and buffer conditions. As an example, the specific activity of PET hydrolysis corresponds to μmol of PET hydrolyzed per mg of enzyme and per minute or mg of equivalent TA produced per hour, as determined in the linear portion of the hydrolysis curve.

[0049] The ability of a protein to adsorb onto a substrate can be evaluated by the skilled artisan according to methods known per se in the art, for example, the protein content or the residual esterase activity, the residual polyester depolymerization activity, the residual degradation of solid polyester compounds dispersed on an agar plate, or the residual polyester depolymerization activity in a reactor can be measured from a solution containing the esterase of the invention, which has been previously incubated with the substrate under suitable conditions in which no enzymatic reaction can take place.

[0050] The esterases of the invention may contain one or several modifications as disclosed below.

[0051] In one embodiment, the esterase of the invention has at least 75%, 80%, 85%, 90%, 95%, or 99% identity to the full-length amino acid sequence shown in SEQ ID NO:1 and contains at least one additional disulfide bridge compared to the esterase of SEQ ID NO:1.

[0052] In a particular embodiment, the esterase variant comprises a substitution at positions A172+A209, where positions are numbered with reference to the amino acid sequence shown in SEQ ID NO:1.

[0053] In another specific embodiment, the esterase variant comprises at least one mutation at a position selected from V28 to G39, L82, and A103, where the positions are numbered with reference to the amino acid sequence set forth in SEQ ID NO:1.

[0054] In particular, the esterase variant exhibits a deletion of amino acid residues V28 to S34 of SEQ ID NO:1 and substitutions at positions selected from G35, F36, G37, G38, G39, L82 and / or A103 compared to SEQ ID NO:1, more particularly substitutions consisting of G35E / A + F36G + G37P + G38S + G39C, L82A and / or A103C.

[0055] Alternatively, the esterase variant exhibits a deletion of amino acids V33 to G39 of SEQ ID NO: 1 and a substitution consisting of V28E+S29G+R30P+L31S+S32C or V28A+S29G+R30P+L31S+S32C compared to SEQ ID NO: 1, as well as the substitutions L82A and / or A103C.

[0056] Alternatively, the esterase mutant comprises a substitution of amino acids V28 to G39 of SEQ ID NO: 1 with an amino acid sequence consisting of EGPSC or AGPSC, and finally the substitutions L82A and / or A103C.

[0057] Alternatively, the esterase variant exhibits a deletion of amino acids V33 to G39 of SEQ ID NO:1, as well as substitutions consisting of V28E+S29G+R30P+L31S+S32C or V28A+S29G+R30P+L31S+S32C, as well as substitutions L82A, A103C, A172C, and A209C.

[0058] In another particular embodiment, the esterase variant comprises a substitution at position D203+S248, where the positions are numbered by reference to the amino acid sequence shown in SEQ ID NO:1. Preferably, the substitution consists of D203C+S248C. In a particular embodiment, such an esterase variant having a substitution at position D203C+S248 further comprises at least one substitution at a position selected from E173, L202, N204, and F208. Preferably, the additional substitution is selected from E173R, E173A, F208W, or F208I. More particularly, the esterase variant comprises a substitution selected from D203C+S248C+E173R, D203C+S248C+E173A, D203C+S248C+F208W, and D203C+S248C+F208I. In certain embodiments, the esterase variant having a substitution at position D203+S248 further comprises at least two substitutions at positions selected from E173, L202, N204, and F208. For example, the variant comprises at least the following substitutions: D203C + S248C + E173R + N204D + L202R, F208W + D203C + S248C + E173A, and F208I + D203C + S248C + E173A.

[0059] The object of the present invention is to provide an esterase with polyesterolytic activity which has at least 75%, 80%, 85%, 90%, 95% or 99% identity to the full-length amino acid sequence shown in SEQ ID NO: 1 and which comprises at least one mutation of an amino acid residue located in a solvent-excluded cavity of the protein cavity compared to SEQ ID NO: 1. In particular, such a mutation makes it possible to reduce the solvent-excluded volume of the cavity.

[0060] In a particular embodiment, the esterase variant comprises at least one substitution at a position selected from G53, L104, L107, L119, A121, L124, I54, M56, L70, L74, A127, V150, L152, L168, V170, P196, V198, V200, V219, Y220, T221, S223, W224, M225, L239, T252, N253, H256, with reference to SEQ ID NO: 1. Advantageously, the esterase variant comprises at least two, three, four, five or more amino acid substitutions between said positions.

[0061] In one embodiment, at least one of the amino acids is replaced by a bulkier (ie, larger volume) amino acid.

[0062] Advantageously, the esterase variant comprises at least one substitution selected from G53A / I, I54L, M56I, L70M / I, L74M, L104M, L107M, L119M / A, A121V / I / M / Y, L124I / R / Q, A127V / I, V150I, L152I, L168I, V170I, V198I, V219I, Y220F / P / M, T221A / V / L / I / M, S223A, W224I / M, and T252S / D.

[0063] In a particular embodiment, the esterase variant comprises a substitution at position V170+F208. Advantageously, the esterase variant comprises a substitution V170I+F208W.

[0064] In a particular embodiment, the esterase variant comprises an amino acid substitution at a position belonging to at least two of the following groups (i) to (v): Advantageously, the esterase variant comprises at least a substitution at a position in each of groups (i) to (v). (i)G53, L104, L107, L119, A121, L124; (ii)I54, M56, L70, L74, A127, V150, L152, T221, M225; (iii)V150, L152, L168, V170, V200, T221; (iv)P196, V198, W224, T252, N253, H256; (v) V219, Y220, S223, L239

[0065] It is an object of the present invention to provide an esterase with polyesterolytic activity which has at least 75%, 80%, 85%, 90%, 95% or 99% identity to the full-length amino acid sequence shown in SEQ ID NO: 1 and which comprises at least one additional salt bridge compared to SEQ ID NO: 1. Preferably, the esterase comprises at least one additional surface salt bridge, which is located on the outer surface of the protein structure.

[0066] To this end, the esterase variant advantageously comprises at least one amino acid substitution at a position selected from S1, Y4, Q5, R6, N9, S13, T16, S22, T25, Y26, S34, Y43, S48, T50, R72, S98, N105, R108, S113, N122, S145, K147, T160, N162, E173, S181, Q189, N190, S193, T194, D203, N204, S212, N213, N231, T233, R236, Q237, N241, N243, N254, R255, Q258.

[0067] Advantageously, the esterase mutant has at least one salt bridge between the two amino acids at said position.

[0068] Often, the salt bridge is formed by interaction between the anionic charge of either aspartic acid (D) or glutamic acid (E) and the cationic charge of either lysine (K) or arginine (R). Thus, the salt bridge in the esterase of the invention is advantageously obtained by substituting at least one amino acid of at least one target amino acid pair as listed in Table 1 with D or E and / or K or R, depending on the nature of the target amino acid pair under consideration.

[0069] [Table 1]

[0070] Advantageously, when the amino acid residue of the targeted amino acid pair is R or K, only the second amino acid of the targeted pair is substituted with D or E. As an example, the esterase variant of the invention may comprise the amino acid substitution Y4D, which may exhibit a salt bridge between said mutated amino acid residue and R6. Similarly, when the amino acid residue of the targeted amino acid pair is D or E, only the second amino acid of the targeted pair is substituted with R or K. As an example, the esterase variant of the invention may comprise the amino acid substitution N204R, which may exhibit a salt bridge between said mutated amino acid residue and E173.

[0071] It is also an object of the present invention to provide esterases with polyesterolytic activity which have at least 75%, 80%, 85%, 90%, 95% or 99% identity to the full-length amino acid sequence shown in SEQ ID NO:1 and which comprise the suppression of at least one N-terminal and / or C-terminal amino acid residue compared to SEQ ID NO:1, preferably the suppression of at least one N-terminal amino acid residue.

[0072] In certain embodiments, esterase variants of the invention comprise one or more amino acid substitution(s) compared to SEQ ID NO:1 at a position selected from T61, Y92, and V177, where the positions are numbered with reference to the amino acid sequence set forth in SEQ ID NO:1, and where the substitution(s) are different from T61A / G, Y92A, and V177A. Preferably, esterase variants of the invention comprise one or more amino acid substitution(s) selected from V177I, Y92G / P, and T61M, compared to SEQ ID NO:1.

[0073] In another particular embodiment, the esterase variant of the invention comprises at least one substitution at position F208 compared to SEQ ID NO: 1. According to the invention, F208 may be substituted by any one of 19 other amino acids. Preferably, the substitution is F208W.

[0074] In another particular embodiment, said esterase variant comprises at least two substitutions at positions selected from T61, Y92, V177 and F208 compared to SEQ ID NO:1, preferably at least two substitutions at positions F208 and Y92.

[0075] In a particular embodiment, said variant comprises at least the substitutions Y92P+F208W.

[0076] In another particular embodiment, said variant comprises at least the V170I+F208W substitutions.

[0077] According to the invention, said esterase variants may be further glycosylated to further increase the thermostability of the enzyme compared to the enzyme of SEQ ID NO:1.

[0078] In certain embodiments, the esterase variants comprise a glycosylation moiety on at least one asparagine residue of the enzyme, preferably at a position selected from N9, N143, N162, N204, N231, more preferably at a position selected from N9, N162, and N231, with reference to SEQ ID NO: 1. In one embodiment, the esterase variants comprise a glycosylation moiety at N9, N162, and N231.

[0079] For example, the N-linked glycan moiety is attached to at least one nitrogen of the asparagine residue.

[0080] Alternatively or additionally, the esterase variants of the invention may further comprise one or more insertions of proline residues and / or one or more deletions of glycines.

[0081] In a particular embodiment, the esterase variant of the invention comprises one or several modifications and / or mutations as listed above.

[0082] Novel esterases with both improved thermostability and activity It is a further object of the present invention to provide novel esterases which exhibit both improved thermostability and improved polyesterolytic activity as compared to the esterase of SEQ ID NO:1.

[0083] Accordingly, another object of the present invention is to provide an esterase that (i) has at least 75%, 80%, 85%, 90%, 95%, or 99% identity to the full-length amino acid sequence shown in SEQ ID NO:1, (ii) contains at least one amino acid modification compared to SEQ ID NO:1, and (iii) exhibits both improved thermostability and improved activity compared to the esterase of SEQ ID NO:1.

[0084] In a particular embodiment, said esterase variant comprises at least one mutation as disclosed above with reference to SEQ ID NO:1 and at least one additional substitution selected from F280I or F208W.

[0085] In another particular embodiment, the mutant is The esterase comprises at least one substitution selected from T61M, Y92G / P, F208W, Y92P + F208W, and F208W + V170I, and exhibits both improved thermostability and improved activity compared to the esterase of SEQ ID NO:1.

[0086] In a particular embodiment, the mutant is The esterase comprises at least a substitution(s) selected from F208W + D203C + S248C and F208I + D203C + S248C, and exhibits both improved thermostability and improved activity compared to the esterase of SEQ ID NO:1.

[0087] Polyester decomposition activity The object of the present invention is to provide novel enzymes having esterase activity. In a particular embodiment, the enzymes of the present invention further exhibit cutinase activity.

[0088] In a particular embodiment, the esterases of the invention have polyester degrading activity, preferably polyethylene terephthalate (PET) degrading activity.

[0089] In another particular embodiment, the esterases of the invention also have PBAT degrading activity.

[0090] Advantageously, the esterase variants of the invention exhibit polyester degrading activity at least in the temperature range of 20° C. to 90° C., preferably 40° C. to 80° C., more preferably 50° C. to 70° C., even more preferably 6 ...5° C. In a particular embodiment, the esterase variants of the invention exhibit polyester degrading activity at 70° C. In another particular embodiment, polyester degrading activity is still measurable at temperatures between 60° C. and 90° C.

[0091] In certain embodiments, the esterase variants of the invention have an extended half-life at a given temperature compared to the esterase of SEQ ID NO: 1, more particularly at temperatures between 40° C. and 80° C., more preferably between 50° C. and 70° C., even more preferably between 60° C. and 70° C., and even more preferably at 65° C. In certain embodiments, the esterase variants have a half-life at 65° C. that is at least 5% longer than the half-life of the esterase of SEQ ID NO: 1, and preferably at least 10%, 20%, 50%, 100%, 200%, 300% or more longer.

[0092] In another particular embodiment, the esterase variants of the invention have an increased melting temperature (Tm) compared to the esterase of SEQ ID NO: 1. Advantageously, the esterase variants of the invention have an increased melting temperature (Tm) of about 1° C., 2° C., 3° ​​C., 4° C., 5° C., 10° C., or more compared to the esterase of SEQ ID NO: 1.

[0093] In certain embodiments, the esterase variants of the invention exhibit measurable esterase activity at least in the pH range of 5-11, preferably in the pH range of 6-9, more preferably in the pH range of 6.5-9, and even more preferably in the pH range of 6.5-8.

[0094] Nucleic acids, expression cassettes, and vectors A further object of the present invention is to provide a nucleic acid encoding an esterase as defined above.

[0095] As used herein, the terms "nucleic acid", "nucleic acid sequence", "polynucleotide", "oligonucleotide" and "nucleotide sequence" are used interchangeably and refer to deoxyribonucleotide and / or ribonucleotide sequences. The nucleic acid may be DNA (cDNA or gDNA), RNA, or a mixture of the two. It may be in single-stranded or double-stranded form, or a mixture of the two. It may be of recombinant, artificial, and / or synthetic origin, and it may contain modified nucleotides, including, for example, modified bonds, modified purine or pyrimidine bases, or modified sugars. The nucleic acids of the invention may be in isolated or purified form and may be produced, isolated, and / or manipulated by techniques known per se in the art, such as, for example, by cloning and expression of cDNA libraries, amplification, enzymatic synthesis, or recombinant techniques. Nucleic acids may also be synthesized in vitro by well-known chemical synthesis techniques, for example, as described in Belousov (1997) Nucleic Acids Res. 25:3440-3444.

[0096] The present invention also encompasses nucleic acids that hybridize under stringent conditions to nucleic acids encoding esterases as defined above. Preferably, such stringent conditions include incubating the hybridization filter in 2xSSC / 0.1% SDS at about 42°C for about 2.5 hours, followed by washing the filter four times for 15 minutes at 65°C with 1xSSC / 0.1% SDS. The protocols used are described in references such as Sambrook et al. (Molecular Cloning: a Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor NY (1988)) and Ausubel (Current Protocols in Molecular Biology (1989)).

[0097] The invention also encompasses a nucleic acid encoding an esterase of the invention, wherein the sequence of the nucleic acid, or at least a portion of the sequence, has been engineered using optimized codon usage.

[0098] Alternatively, the nucleic acid according to the invention can be deduced from the sequence of the esterase according to the invention, and the codon usage can be adapted depending on the host cell in which the nucleic acid will be transcribed. These steps can be carried out according to methods well known to those skilled in the art, some of which are described in the reference manual of Sambrook et al. (Sambrook et al., 2001).

[0099] The nucleic acids of the present invention may further comprise additional nucleotide sequences, such as regulatory regions, i.e., promoters, enhancers, silencers, terminators, signal peptides, etc., that can be used to cause or regulate expression of the polypeptide in a selected host cell or host system.

[0100] The present invention further relates to an expression cassette comprising a nucleic acid according to the present invention operably linked to one or more control sequences directing the expression of said nucleic acid in a suitable host cell. Typically, the expression cassette comprises or consists of a nucleic acid according to the present invention operably linked to control sequences such as a transcription promoter and / or a transcription terminator. The control sequence may comprise a promoter recognized by a host cell or an in vitro expression system for the expression of the nucleic acid encoding the esterase of the present invention. The promoter contains a transcription control sequence that mediates the expression of the enzyme. The promoter, including mutated promoters, truncated promoters, and hybrid promoters, may be any polynucleotide that exhibits transcriptional activity in a host cell and may be obtained from a gene encoding an extracellular or intracellular polypeptide that is either homologous or heterologous to the host cell. The control sequence may also be a transcription terminator recognized by the host cell to terminate transcription. The terminator is operably linked to the 3' end of the nucleic acid encoding the esterase. Any terminator that is functional in the host cell may be used in the present invention. Typically, an expression cassette comprises or consists of a nucleic acid according to the invention operably linked to a transcription promoter and a transcription terminator.

[0101] The present invention also relates to a vector comprising a nucleic acid or an expression cassette as defined above.

[0102] The term "vector" refers to a DNA molecule used as a vehicle to introduce recombinant genetic material into a host cell. The main types of vectors are plasmids, bacteriophages, viruses, cosmids, and artificial chromosomes. The vector itself is generally a DNA sequence consisting of an insert (heterologous nucleic acid sequence, transgene) and a larger sequence that serves as the "backbone" of the vector. The purpose of a vector to introduce genetic information into a host is typically to isolate, replicate, or express the insert in a target cell. Vectors called expression vectors (expression constructs) are specifically adapted for the expression of heterologous sequences in target cells and generally have a promoter sequence that drives the expression of a heterologous sequence that codes for a polypeptide. Generally, the regulatory sequences present in an expression vector include a transcription promoter, a ribosome binding site, a terminator, and an operator that is optionally present. Preferably, an expression vector also contains an origin of replication for autonomous replication in the host cell, a selection marker, a small number of useful restriction enzyme sites, and a capacity for high copy number. Examples of expression vectors are cloning vectors, modified cloning vectors, specifically designed plasmids, and viruses. Expression vectors that confer appropriate levels of polypeptide expression in a variety of hosts are well known in the art. The choice of vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced.

[0103] Another object of the invention is to provide a host cell comprising a nucleic acid, an expression cassette or a vector as described above. The invention therefore relates to the use of a nucleic acid, an expression cassette or a vector according to the invention for transforming, transfecting or transducing a host cell. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which it has to be introduced.

[0104] According to the present invention, the host cell may be transiently or stably transformed, transfected or transduced. The expression cassette or vector of the present invention is introduced into the host cell, whereby the cassette or vector is maintained as a chromosomal integrant or as a self-replicating extrachromosomal vector. The term "host cell" also encompasses any progeny of a parent host cell that is not identical to the parent host cell due to mutations that occur during replication. The host cell, e.g., a prokaryotic or eukaryotic cell, may be any cell useful in the generation of the variants of the present invention. The prokaryotic host cell may be any gram-positive or gram-negative bacterium. The host cell may also be a eukaryotic cell, e.g., a yeast, fungus, mammalian, insect, or plant cell. In certain embodiments, the host cell is selected from the group of Escherichia coli, Bacillus, Streptomyces, Trichoderma, Aspergillus, Saccharomyces, Pichia, or Yarrowia.

[0105] The nucleic acids, expression cassettes, or expression vectors according to the invention can be introduced into host cells by any method known to those skilled in the art, such as, for example, electroporation, conjugation, transduction, competent cell transformation, protoplast transformation, protoplast fusion, biolistic "gene gun" transformation, PEG-mediated transformation, lipid-assisted transformation or transfection, chemically mediated transfection, lithium acetate-mediated transformation, liposome-mediated transformation.

[0106] Optionally, one or more copies of a nucleic acid, cassette or vector of the invention may be inserted into the host cell to increase the production of mutants.

[0107] In a particular embodiment, the host cell is a recombinant microorganism. The present invention indeed allows the engineering of microorganisms with improved ability to degrade polyester-containing materials. For example, the sequences of the present invention can be used to complement wild-type strains of fungi or bacteria already known to be capable of degrading polyesters, to improve and / or enhance the performance of the strains.

[0108] Generation of esterase mutants Another object of the invention is to provide a method for producing an esterase variant of the invention comprising the steps of expressing a nucleic acid encoding the esterase and optionally recovering the esterase.

[0109] In particular, the present invention relates to a method for in vitro production of an esterase of the present invention, comprising the steps of: (a) contacting a nucleic acid, cassette, or vector of the present invention with an in vitro expression system; and (b) recovering the produced esterase. In vitro expression systems are well known to those skilled in the art and are commercially available.

[0110] Preferably, the method of production comprises: (a) culturing a host cell containing a nucleic acid encoding an esterase of the invention under conditions suitable for expressing said nucleic acid; and optionally (b) recovering the esterase from the cell culture. Includes.

[0111] Advantageously, the host cell is a recombinant Bacillus, a recombinant E. coli, a recombinant Aspergillus, a recombinant Trichoderma, a recombinant Streptomyces, a recombinant Saccharomyces, a recombinant Pichia, or a recombinant Yarrowia lipolytica.

[0112] The host cells are cultured in a nutrient medium suitable for the production of the polypeptide using methods known in the art. For example, the cells may be cultured by shake flask culture or small- or large-scale fermentation (including continuous, batch, fed-batch, or solid-state fermentation) carried out in a suitable medium and under conditions that allow the enzyme to be expressed and / or isolated. Cultivation is carried out in a suitable nutrient medium prepared according to a published composition from a commercial supplier or published in the catalogue of the American Type Culture Collection, for example.

[0113] If the esterase is secreted into the nutrient medium, it can be directly recovered from the culture supernatant. Conversely, the esterase can be recovered from the cell lysate or after permeabilization. The esterase can be recovered using any method known in the art. For example, the esterase can be recovered from the nutrient medium by conventional procedures, including but not limited to, recovery, centrifugation, filtration, extraction, spray drying, evaporation, or precipitation. Optionally, the esterase can be partially or completely purified by various procedures known in the art, including but not limited to, chromatography (e.g., ion exchange chromatography, affinity chromatography, hydrophobic chromatography, isoelectric focusing, and size exclusion chromatography), electrophoretic techniques (e.g., preparative isoelectric focusing), solubility differences (e.g., ammonium sulfate precipitation), SDS-PAGE, or extraction to obtain a substantially pure polypeptide.

[0114] The esterase can therefore be used in purified form, either alone or in combination with additional enzymes, to catalyze enzymatic reactions involved in the degradation and / or recycling of polyester-containing materials, such as polyester-containing plastic products. The esterase can be in soluble form or present on a solid phase. In particular, it can be bound to cell membranes or lipid vesicles, or to synthetic supports such as glass, plastic, polymers, filters, membranes, for example in the form of beads, columns, plates, etc.

[0115] composition A further object of the present invention is to provide a composition comprising an esterase or a host cell of the present invention. In the context of the present invention, the term "composition" includes any type of composition comprising an esterase of the present invention. In a particular embodiment, the esterase is in isolated or at least partially purified form.

[0116] The composition may be in liquid or dry form, for example in the form of a powder. In some embodiments, the composition is a lyophilizate. For example, the composition may include the esterase and / or recombinant cells encoding the esterase of the invention or an extract thereof, and optionally excipients and / or reagents, etc. Suitable excipients include buffers commonly used in biochemistry, pH adjusters, preservatives such as sodium benzoate, sodium sorbate, or sodium ascorbate, preservatives, protectants, or stabilizers such as starch, dextrin, gum arabic, salts, sugars such as sorbitol, trehalose, or lactose, glycerol, polyethylene glycol, polyethene glycol, polypropylene glycol, propylene glycol, sequestrants such as EDTA, reducing agents, amino acids, carriers such as solvents or aqueous solutions, etc. The composition of the invention may be obtained by mixing the esterase with one or several excipients.

[0117] The composition of the present invention may comprise 0.1% to 99.9% by weight, preferably 0.1% to 50% by weight, more preferably 0.1% to 30% by weight, even more preferably 0.1% to 5% by weight of the esterase of the present invention, and 0.1% to 99.9% by weight, preferably 50% to 99.9% by weight, more preferably 70% to 99.9% by weight, even more preferably 95% to 99.9% by weight of excipient(s). A preferred composition comprises 0.1% to 5% by weight of the esterase of the present invention.

[0118] In certain embodiments, the composition may further comprise additional polypeptide(s) exhibiting enzymatic activity. The amount of the esterase of the present invention will be easily adapted by the skilled artisan depending, for example, on the nature of the polyester-containing material to be degraded and / or the additional enzymes / polypeptides contained in the composition.

[0119] In a particular embodiment, the esterase of the invention is solubilized in an aqueous medium together with one or several excipients, in particular excipients capable of stabilizing or protecting the polypeptide from degradation. For example, the esterase of the invention can be solubilized in water, eventually with additional components such as glycerol, sorbitol, dextrin, starch, glycols, such as propanediol, salts, etc. The resulting mixture can then be dried to obtain a powder. Methods for drying such mixtures are well known to those skilled in the art and include, but are not limited to, lyophilisation, freeze-drying, spray drying, supercritical drying, down-draught evaporation, thin layer evaporation, centrifugal evaporation, conveyor drying, fluidized bed drying, drum drying, or any combination thereof.

[0120] In a further particular embodiment, the composition of the invention comprises at least one recombinant cell expressing the esterase of the invention or an extract thereof. "Extract of cells" refers to any fraction obtained from a cell that is substantially free of viable cells, such as cell supernatant, cell debris, cell wall, DNA extract, enzyme or enzyme preparation, or any preparation derived from a cell by chemical, physical and / or enzymatic treatment. Preferred extracts are enzymatically active extracts. The composition of the invention may comprise one or several recombinant cells of the invention or extracts thereof, and optionally one or several additional cells.

[0121] In certain embodiments, the composition consists of or comprises lyophilized culture medium of a recombinant microorganism expressing and secreting an esterase of the invention. In certain embodiments, the powder comprises an esterase of the invention and a stabilizing / solubilizing amount of glycerol, sorbitol or dextrin, such as maltodextrin and / or cyclodextrin, starch, glycol, such as propanediol, and / or salt.

[0122] Uses of the Esterases of the Invention It is a further object of the present invention to provide methods of using the esterases of the present invention to degrade under aerobic and / or anaerobic conditions and / or to recycle polyester-containing materials, such as plastic products made from or containing polyester. The esterase variants of the present invention are particularly useful for degrading plastic products, including PET.

[0123] It is therefore an object of the present invention to use the esterases of the present invention, or corresponding recombinant cells or extracts thereof, or compositions, for the enzymatic degradation of polyester-containing materials, such as PET-containing materials.

[0124] Another object of the present invention is to provide a method for degrading a plastic product containing at least one polyester, wherein the plastic product is degraded by contacting the plastic product with an esterase or a host cell or a composition of the present invention. Advantageously, the polyester(s) of the polyester-containing material are depolymerized to monomers and / or oligomers.

[0125] In one embodiment of the degradation process, at least one polyester is degraded to obtain repolymerizable monomers and / or oligomers, which are advantageously recovered for reuse.

[0126] In one embodiment, the polyester(s) of the polyester-containing material are completely degraded.

[0127] In a particular embodiment, the plastic article comprises at least one polyester, preferably polyethylene terephthalate, selected from polyethylene terephthalate (PET), polytrimethylene terephthalate (PTT), polybutylene terephthalate (PBT), polyethylene isosorbide terephthalate (PEIT), polylactic acid (PLA), polyhydroxyalkanoic acid (PHA), polybutylene succinate (PBS), polybutylene succinate adipate (PBSA), polybutylene adipate terephthalate (PBAT), polyethylene furanoate (PEF), polycaprolactone (PCL), poly(ethylene adipate) (PEA), polyethylene naphthalate (PEN), and blends / mixtures of these materials. In a preferred embodiment, the polyester-containing material comprises PET and at least monomers, such as monoethylene glycol or terephthalic acid, and / or oligomers, such as methyl-2-hydroxyethyl terephthalate (MHET), bis(2-hydroxyethyl) terephthalate (BHET), 2-hydroxyethyl benzoate (HEB) and dimethyl terephthalate (DMT), are recovered, for example for recycling or methanation.

[0128] The present invention also relates to a method for producing monomers and / or oligomers from a polyester-containing material, comprising exposing the polyester-containing material to an esterase of the present invention or a corresponding recombinant cell or extract or composition thereof, and optionally recovering the monomers and / or oligomers. The method of the present invention is particularly useful for producing monomers selected from monoethylene glycol and terephthalic acid, and / or oligomers selected from methyl-2-hydroxyethyl terephthalate (MHET), bis(2-hydroxyethyl) terephthalate (BHET), 2-hydroxyethyl benzoate (HEB), and dimethyl terephthalate (DMT).

[0129] The time required to degrade the polyester-containing material may vary depending on the polyester-containing material itself (i.e., the nature and source of the plastic product, its composition, shape, etc.), the type and amount of esterase used, and various process parameters (i.e., temperature, pH, additional agents, etc.) A person skilled in the art can easily adapt the process parameters to the polyester-containing material.

[0130] Advantageously, the degradation process is carried out at a temperature between 20°C and 90°C, preferably between 40°C and 80°C, more preferably between 50°C and 70°C, more preferably between 60°C and 70°C, even more preferably at 65°C. In another particular embodiment, the degradation process is carried out at 70°C. More generally, the temperature is kept below the inactivation temperature, which corresponds to the temperature at which the esterase is inactivated and / or at which the recombinant microorganism no longer synthesizes the esterase. In particular, the temperature is kept below the glass transition temperature (Tg) of the polyester in the polyester-containing material. More particularly, the process is carried out at a temperature that allows the esterase to be used and / or recycled several times, continuously.

[0131] Advantageously, the degradation process is carried out at a pH between 5 and 11, preferably at a pH between 6 and 9, more preferably at a pH between 6.5 and 9, even more preferably at a pH between 6.5 and 8.

[0132] In certain embodiments, the polyester-containing material may be pretreated prior to contact with the esterase in order to physically modify its structure, thereby increasing the contact surface between the polyester and the variant of the invention.

[0133] Optionally, the monomers and / or oligomers resulting from the depolymerization may be recovered sequentially or continuously. One type of monomer and / or oligomer, or several types of monomers and / or oligomers may be recovered depending on the starting polyester-containing material.

[0134] The recovered monomers and / or oligomers may be further purified and prepared in a repolymerizable form using any suitable purification method, including stripping processes, separation with aqueous solutions, selective steam condensation, filtration and concentration of post-bioprocessing media, separation, distillation, vacuum evaporation, extraction, electrodialysis, adsorption, ion exchange, precipitation, crystallization, concentration, and acid addition dehydration, and precipitation, nanofiltration, acid catalyzed treatment, semi-continuous or continuous mode distillation, solvent evaporation, evaporative concentration, evaporative crystallization, liquid / liquid extraction, hydrogenation, azeotropic distillation processes, adsorption, column chromatography, simple vacuum distillation, and microfiltration, in combination or not.

[0135] The repolymerizable monomers and / or oligomers can then be reused, for example, to synthesize polyesters. Advantageously, polyesters of the same nature are repolymerized. However, it is possible to mix the recovered monomers and / or oligomers with other monomers and / or oligomers, thereby, for example, synthesizing new copolymers. Alternatively, the recovered monomers may be used as chemical intermediates to produce new compounds of interest.

[0136] The present invention also relates to a method for surface hydrolysis or surface functionalization of polyester-containing materials, comprising exposing the polyester-containing material to an esterase of the present invention or a corresponding recombinant cell or extract or composition thereof. The method of the present invention is particularly useful for increasing the hydrophilicity or water adsorption properties of polyester materials. Such increased hydrophilicity may be of particular interest for textile fabrication, electronics, and biomedical applications.

[0137] A further object of the present invention is to provide a polyester-containing material comprising the esterase of the present invention and / or a recombinant microorganism expressing and secreting the esterase. In a particular embodiment, such a polyester-containing material can be a plastic compound. Thus, an object of the present invention is to provide a plastic compound comprising the esterase of the present invention and / or a recombinant cell and / or a composition or extract thereof; and at least one polyester. In a preferred embodiment, the polyester is PET.

[0138] Working Example Example 1 - Construction, expression, and purification of esterases -construction Esterase mutants were generated using the plasmid construct pET26b-LCC-His, which consists of cloning the gene encoding the esterase of SEQ ID NO: 1, optimized for expression in E. coli, between the NdeI and XhoI restriction enzyme sites. To generate the esterase mutants, two site-directed mutagenesis kits were used according to the manufacturer's recommendations: QuikChange II Site-Directed Mutagenesis Kit and QuikChange Lightning Multi Site-Directed from Agilent (Santa Clara, CA, USA).

[0139] -Expression and purification of esterases Stellar™ strain (Clontech, CA, USA) and E. coli One Shot® BL21 DE3 (Life Technologies, Carlsbad, CA, USA) were successfully used to perform cloning and recombinant expression in 50 mL of LB-Miller medium or ZYM autoinducing medium (Studier et al., 2005- Prot. Exp. Pur. 41, 207-234). Induction in LB-Miller medium was performed at 16°C with 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG, Euromedics, Zouffelweyersheim, France). Cultures were stopped by centrifugation (8000 rpm, 20 min at 10°C) in an Avanti J-26XP centrifuge (Beckman Coulter, Brea, USA). The cells were suspended in 20 mL of Talon buffer (Tris-HCl 20 mM, NaCl 300 mM, pH 8). The cell suspension was then subjected to sonication for 2 min with an FB705 ultrasonicator (Fischerbrand, Illkirch, France) at 30% amplitude (2 sec on, 1 sec off cycle). A centrifugation step was then realised: 11000 rpm in an Eppendorf centrifuge for 30 min at 10°C. The soluble fraction was collected and subjected to affinity chromatography. This purification step was completed with Talon® Metal Affinity Resin (Clontech, CA, USA). Elution of the protein was carried out with a gradient of Talon buffer supplemented with imidazole. The purified protein was dialysed against Talon buffer and then quantified using the Bio-Rad Protein Assay according to the manufacturer's instructions (Life Sciences Bio-Rad, France) and stored at +4°C.

[0140] Example 2 - Evaluation of the thermostability of the esterases of the invention The thermostability of the esterase variants was determined and compared to that of the esterase of SEQ ID NO:1.

[0141] To estimate thermal stability, different methods were used: (1) Circular dichroism of proteins in solution; (2) Residual esterase activity after incubation of the protein at given temperature, time, and buffer conditions; (3) Residual polyester depolymerization activity after incubation of the protein at given temperature, time, and buffer conditions; (4) the ability to degrade a solid polyester compound (e.g., PET or PBAT or analogues) dispersed on an agar plate after incubation of the protein at given temperature, time, and buffer conditions; (5) the ability to perform multiple polyester depolymerization assays at given temperature, buffer, protein concentration, and polyester concentration conditions; (6) Differential scanning fluorimetry (DSF).

[0142] Details regarding the protocol for such a method are provided below.

[0143] 2.1 Circular dichroism Circular dichroism (CD) was performed using a Jasco 815 instrument (Easton, USA) to compare the melting temperatures (Tm) of the esterase of SEQ ID NO: 1 and the esterase variants of the present invention. Tm corresponds to the temperature at which 50% of the protein is denatured.

[0144] Technically, 400 μL of protein sample was prepared at 0.5 mg / mL in Talon buffer and used for CD. A first scan from 280 to 190 nm was realized to determine the two CD intensity maxima corresponding to the correct folding of the protein. A second scan was then performed at wavelengths corresponding to such maximal intensity at 25 °C to 110 °C to obtain a specific curve (sigmoidal three parameters y=a / (1+(1+e^((x-x0) / b))), which was analyzed by Sigmaplot version 11.0 software and the Tm when x=x0 was determined. The obtained Tm reflects the thermal stability of a given protein. The higher the Tm, the more stable the mutant is at high temperatures.

[0145] 2.2 Residual esterase activity 1 mL of a 40 mg / L solution (in Talon buffer) of the esterase or esterase variant of SEQ ID NO:1 was incubated at various temperatures (65, 70, 75, 80, and 90 °C) for 10 days. Samples were taken periodically and diluted 1-500 times with 0.1 M potassium phosphate buffer (pH 8.0) to realize the paranitrophenol-butyrate (pNP-B) assay. 20 μL of sample was mixed with 175 μL of 0.1 M potassium phosphate buffer (pH 8.0) and 5 μL of a 2-methyl-2-butanol solution of pNP-B (40 mM). The enzyme reaction was carried out at 30 °C for 15 min under stirring, and the absorbance at 405 nm was obtained by a microplate spectrophotometer (Versamax, Molecular Devices, Sunnyvale, CA, USA). pNP-B hydrolysis activity (initial rate expressed in μmol pNPB per min) was determined using a standard curve for liberated paranitrophenol in the linear portion of the hydrolysis curve. The half-life of the enzyme at a given temperature corresponds to the time required to lose 50% of the initial activity.

[0146] 2.3 Residual polyester depolymerization activity The crushed crystal preform was immersed in liquid nitrogen and micronized to a fine powder with a size of less than 500 μm using an Ultra Centrifugal Mill ZM200 system. The resulting powder was then sieved. Only the fraction with a size between 250 μm and 500 μm was used for the depolymerization test. The crystallinity of this fraction was measured at 11.5% using a Mettler Toledo DSC3 with a heating rate of 10 °C / min.

[0147] 10 mL of 40 mg / L solutions (in Talon buffer) of the esterase of SEQ ID NO:1 and the esterase variants, respectively, were incubated at various temperatures (65, 70, 75, 80, and 90°C) for 10 to 30 days. Periodically, 1 mL samples were taken and transferred to bottles containing 100 mg of amorphous PET micronized at 250-500 μm and 49 mL of 0.1 M potassium phosphate buffer (pH 8.0) and incubated at 65°C. 150 μL of buffer was sampled periodically. If necessary, samples were diluted with 0.1 M potassium phosphate buffer (pH 8). Then, 150 μL of methanol and 6.5 μL of HCL 6N were added to 150 μL of sample or diluent. After mixing and filtration through a 0.45 μm syringe filter, the samples were loaded onto a UHPLC to monitor the release of terephthalic acid (TA), MHET, and BHET. The chromatographic system used was an Ultimate 3000UHPLC system (Thermo Fisher Scientific, Waltham, MA, USA), including a pump module, an autosampler, a column oven thermostated at 25 °C, and a UV detector at 240 nm. The column used was a Discovery® HS C18 HPLC column (150 × 4.6 mm, 5 μm, equipped with a precolumn, Supelco, Bellefonte, USA). TA, MHET, and BHET were separated at 1 mL / min using a MeOH gradient (30%-90%) in 1 mM H2SO4. The injection was 20 μL of sample. TA, MHET, and BHET were measured under the same conditions as the samples according to standard curves prepared from commercially available TA and BHET and in-house synthesized MHET. PET hydrolysis activity (μmol of PET hydrolyzed per minute or mg of equivalent TA produced per hour) was determined in the linear part of the hydrolysis curve. The equivalent TA corresponds to the sum of the measured TA and the TA contained in the measured MHET and BHET. The half-life of an enzyme at a given temperature corresponds to the time required to lose 50% of the initial activity.

[0148] 2.4 Decomposition of polyester in solid form 20 μL of the enzyme preparation was deposited into wells made in an agar plate containing PET. The preparation of the agar plate was achieved by solubilizing 500 mg of PET in HFIP and pouring this medium into 250 mL of an aqueous solution. After evaporating the HFIP at 52° C., the solution was mixed (v / v) with 0.2 M potassium phosphate buffer (pH 8) containing 3% agar. Approximately 30 mL of the mixture is used to prepare each OmniTray and store at 4° C.

[0149] The diameter of the circular halo formed due to polyester degradation was measured after 24 hours at 60° C. or 65° C. The half-life of the enzyme at a given temperature corresponds to the time required for the diameter of the circular halo to decrease by a factor of two.

[0150] 2.5 Multiple polyester depolymerizations The ability of the esterase to perform successive polyester depolymerization assays was evaluated in an enzyme reactor. A Minibio 500 bioreactor (Apricon Biotechnology, Delft, The Netherlands) was started with 100 mL of 10 mM potassium phosphate buffer (pH 8) containing 3 g amorphous PET and 3 mg LC-esterase. Agitation was set at 250 rpm using a marine impeller. The bioreactor was temperature controlled at 65 °C by immersion in an external water bath. The pH was adjusted to 8 by addition of 3 M KOH. Various parameters (pH, temperature, agitation, base addition) were monitored by BioXpert software V2.95. 1.8 g amorphous PET was added every 20 h. 500 μL of reaction medium was sampled periodically.

[0151] The amounts of TA, MHET, and BHET were determined by HPLC as described in Example 2.3. The amount of EG was determined using an Aminex HPX-87K column (Bio-Rad Laboratories, Hercules, CA, USA) thermostated at 65°C. The eluent was 5 mM K2HPO4 at 0.6 mL / min. The injection volume was 20 μL. Ethylene glycol was monitored using a refractometer.

[0152] The hydrolysis rate was calculated based on the ratio of the molar concentration (TA+MHET+BHET) at a given time to the total amount of TA contained in the initial sample, or based on the ratio of the molar concentration (EG+MHET+2×BHET) at a given time to the total amount of EG contained in the initial sample. The degradation rate is calculated in mg of total TA liberated per hour or mg of total EG liberated per hour.

[0153] The half-life of the enzyme was estimated as the incubation time required to obtain a 50% loss of degradation rate.

[0154] 2.6 Differential Scanning Fluorometry (DSF) DSF was used to assess the thermal stability of the wild-type protein (SEQ ID NO: 1) and its mutants by determining their melting temperature (Tm), i.e. the temperature at which half of the protein population is unfolded. Protein samples were prepared at a concentration of 14 μM (0.4 mg / mL) and stored in buffer A consisting of 20 mM Tris-HCl (pH 8.0), 300 mM NaCl. A 5000x stock solution of SYPRO orange dye in DMSO was first diluted 250x with water. Protein samples were loaded into a white clear 96-well PCR plate (Bio-Rad, product no. HSP9601), with each well containing a final volume of 25 μl. The final concentrations of protein and SYPRO orange dye in each well were 5 μM (0.14 mg / ml) and 10x, respectively. The volumes loaded per well were as follows: 15 μL of Buffer A, 9 μL of 0.4 mg / mL protein solution, and 1 μL of 250x Sypro Orange dilution. The PCR plate was then sealed with optical quality sealing tape and centrifuged at 2000 rpm for 1 min at room temperature. DSF experiments were then performed using a CFX96 Real-Time PCR System set to use a 450 / 490 excitation filter and a 560 / 580 emission filter. Samples were heated from 25°C to 100°C at a rate of 1.1°C / min. One fluorescence measurement was taken every 0.3°C. Melting points were determined by fitting the curve to the Boltzmann equation.

[0155] The wild-type protein and mutants were then compared based on their Tm values. Due to the high reproducibility between experiments on the same protein from different generations, a ΔTm of 0.8°C was deemed significant for comparing mutants. Tm values ​​represent the average of at least two measurements.

[0156] The comparative thermostabilities of the esterase variants of the invention are shown in Table 2 below, expressed as Tm values, and evaluated according to Example 2.6. The increase in Tm compared to the esterase of SEQ ID NO: 1 is indicated in brackets.

[0157] [Table 2]

[0158] Example 3 - Evaluation of thermostability and activity of esterase variants of the invention The specific degradation activity of the esterase mutants of the present invention for PET was evaluated and compared with that of the esterase of SEQ ID NO:1.

[0159] 100 mg of amorphous PET was weighed and introduced into a 100 mL vial. 1 mL of esterase preparation (as a reference control) or mutant preparation was prepared at 0.02 or 0.03 mg / mL, respectively, in Talon buffer (Tris-HCl 20 mM, NaCl 0.3 M, pH 8) and introduced into the vial. Finally, 49 mL of 0.1 M potassium phosphate buffer (pH 8) was added.

[0160] Depolymerization was initiated by incubating each vial at 65°C and 150 rpm in a MaxQ4450 incubator (Thermo Fisher Scientific, Waltham, MA, USA).

[0161] The initial rate of the depolymerization reaction (mg of equivalent TA produced per hour) was determined by sampling performed at various time points during the first 24 hours and analyzed by ultra-high performance liquid chromatography (UHPLC). If necessary, the samples were diluted with 0.1 M potassium phosphate buffer (pH 8). Then, 150 μL of methanol and 6.5 μL of HCl 6N were added to 150 μL of sample or diluent. After mixing and filtration through a 0.45 μm syringe filter, the samples were loaded onto the UHPLC and the release of terephthalic acid (TA), MHET and BHET was monitored. The chromatography system used was an Ultimate 3000UHPLC system (Thermo Fisher Scientific, Waltham, MA, USA), including a pump module, an autosampler, a column oven thermostated at 25°C, and a UV detector at 240 nm. The column used was a Discovery® HS C18 HPLC column (150 × 4.6 mm, 5 μm, equipped with a precolumn, Supelco, Bellefonte, USA). TA, MHET, and BHET were separated at 1 mL / min using a MeOH gradient (30%-90%) in 1 mM H2SO4. The injection was 20 μL of sample. TA, MHET, and BHET were measured under the same conditions as the samples according to standard curves prepared from commercially available TA and BHET and in-house synthesized MHET. The specific degradation activity of PET (mg of equivalent TA per hour per mg of enzyme) was determined in the linear part of the hydrolysis curve.

[0162] The results of both the specific degradation activity and the thermostability of the esterase mutants of the present invention are shown in Table 3.

[0163] The specific degradation activity of the esterase of SEQ ID NO:1 is used as a reference and is considered as 100% degradation activity. Degradation activity is measured as shown in Example 3 (mg equivalent TA per hour per mg enzyme). Equivalent TA corresponds to the sum of the measured TA and the TA contained in the measured MHET and BHET. Thermostability is expressed as Tm value (measured according to Example 2.6), the increase in Tm compared to the Tm of the esterase of SEQ ID NO:1 is noted in brackets.

[0164] [Table 3]

Claims

1. (i) having at least 75%, 80%, 85%, 90%, 95%, or 99% identity to the full-length amino acid sequence set forth in SEQ ID NO:1; (ii) D203+S248, E173, L202, N204, F208, A172+A209, G39, A103, L82, G53, L104, L107, L119, A121, L124, I54, M56, L70, L74, A127, V150, L152, L168, V170, P196, V198, V200, V219, Y220, T221, S223, W224, M225, L239, T252, N253, H256, S1, Y4, Q5, R6, N9, S13, T16, S22, T25, Y26, S34, Y43, S48, T50, R72, S98, N105, R108, S113, N122, S145, K147, T160, N162, S181, Q189, N190, S193, T194, N204, S212, N213, N231, T233, R236, Q237, N241, N243, N254, R255 and Q258, preferably D203+S248, E173, N204, L202, and having one or more amino acid modifications compared to SEQ ID NO:1 at a position(s) selected from D203+S248 and F208, and V170, more preferably selected from D203+S248 and F208, wherein the positions are numbered by reference to the amino acid sequence shown in SEQ ID NO:1; (iii) having polyester decomposition activity; (iv) exhibits improved thermostability compared to the esterase of SEQ ID NO:1; Esterase mutants.

2. With reference to the esterase of SEQ ID NO: 1: at least one additional disulfide bridge; and / or at least one additional salt bridge; and / or - at least one mutation of an amino acid residue located in a solvent-exclusion cavity of the esterase cavity; and / or - suppression of at least one N-terminal and / or C-terminal amino acid residue The esterase variant of claim 1 , comprising:

3. - the amino acid substitution D203C+S248C; and / or the amino acid substitution G39C+A103C+L82A and the replacement of amino acids V28 to G39 of SEQ ID NO: 1 with the amino acid sequence E-G-P-S-C or A-G-P-S-C The esterase variant of claim 1 or 2, comprising:

4. 4. The esterase variant of any one of claims 1 to 3, comprising at least one substitution at a position selected from E173, L202, N204 and F208 (wherein the positions are numbered with reference to the amino acid sequence shown in SEQ ID NO:1), preferably at least one substitution selected from E173A / R, L202R, N204D, and F208W.

5. 5. The esterase variant of any one of claims 1 to 4, comprising one or more amino acid substitution(s) compared to SEQ ID NO:1 at a position selected from T61, Y92 and V177, wherein the positions are numbered by reference to the amino acid sequence shown in SEQ ID NO:1, and wherein the substitution(s) are different from T61A / G, Y92A and V177A, and wherein the substitution(s) are preferably selected from V177I, Y92G, Y92P, Y92P+F208W and T61M.

6. 6. The esterase variant of any one of claims 1 to 5, comprising a substitution at a position selected from D203+S248+E173, D203+S248+F208, and D203+S248+E173+N204+L202.

7. 7. The esterase variant of any one of claims 1 to 6, comprising substitutions selected from: D203C + S248C + E173R, D203C + S248C + E173A, D203C + S248C + F208W D203C + S248C + F208I, F208W + D203C + S248C + E173A, F208I + D203C + S248C + E173A and D203C + S248C + E173R + N204D + L202R.

8. The esterase variant of any one of claims 1 to 7, which is glycosylated, preferably at positions selected from N9, N143, N162, N204, N231, or a combination thereof.

9. A nucleic acid encoding an esterase as defined in any one of claims 1 to 7.

10. 10. An expression cassette or vector comprising the nucleic acid of claim 9.

11. 11. A host cell comprising the nucleic acid of claim 9 or the expression cassette or vector of claim 10.

12. (a) culturing the host cell of claim 11 under conditions suitable for expressing the nucleic acid encoding the esterase; and, optionally, (b) recovering the esterase from the cell culture. a method for producing said esterase comprising:

13. A composition comprising an esterase according to any one of claims 1 to 7 and / or a nucleic acid according to claim 9, and / or an expression cassette or vector according to claim 9, and / or a host cell or an extract thereof according to claim 11, and optionally one or several excipients or additives.

14. (a) degrading a plastic product by contacting said plastic product with an esterase according to any one of claims 1 to 7, or with a host cell according to claim 11, or with a composition according to claim 13; and optionally (b) recovering the monomers and / or oligomers 1. A method for degrading a plastic article containing at least one polyester, comprising:

15. 15. The method of claim 14, wherein the plastic product comprises at least one polyester, preferably polyethylene terephthalate, selected from polyethylene terephthalate (PET), polytrimethylene terephthalate (PTT), polybutylene terephthalate (PBT), polyethylene isosorbide terephthalate (PEIT), polylactic acid (PLA), polyhydroxyalkanoic acid (PHA), polybutylene succinate (PBS), polybutylene succinate adipate (PBSA), polybutylene adipate terephthalate (PBAT), polyethylene furanoate (PEF), polycaprolactone (PCL), poly(ethylene adipate) (PEA), polyethylene naphthalate (PEN), and blends / mixtures of these materials.

16. The process of claim 14 or 15, wherein step (a) is carried out at a temperature of from 50°C to 90°C, preferably from 60°C to 70°C.

Images